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ABSTRACT 
 
OBJECTIVE: To determine whether or not the Phosphodiesterase inhibitors drug Sildenafil 
Citrate is safe and effective treatment for Pulmonary Hypertension in adults 
 
STUDY DESIGN: reviewed primary research materials published in English language between 
1996 and 2009 
 
DATA SOURCES: Randomized, controlled, double-blind clinical trials found using OVID, 
MEDLINE, and Cochrane data bases 
 
OUTCOME MEASURED: trials measured 6-minute walking distance improvement, 
hemodynamic measurements to asses vascular resistance, peak VO2 
 
RESULTS: two randomized trials included in this review showed Sildenafil is effective in 
treating PAH. The trials showed patients had an improvement their 6-minute walking distance, 
quality of life improvement, and decreased vascular resistance. A trial conducted by Shim et al 
was in conclusive needing further research as it is one of the only trials that tried to determine the 
effect of Sildenfil in patients who are undergoing cardiac surgery  
 
CONCLUSIONS: Sidenfil provides symptomatic relief with little side effects in patients 
suffering from PAH. Two of the researches showed that sidenfil did have an efficacy in treating 
PAH by decreasing vascular resistance.  
 
KEY WORDS: Sildenafil, Viagra, pulmonary hypertension, pulmonary atrial hyper tension 
 
 
 
 
 
 
 
 
 
 
 
Atekelt Tadese 
Sildenafil efficacy in treatment of PAH   2 
 
 
INTRODUCTION  
Pulmonary Hypertension is a very rare disease that is caused by an increase in pressure in 
pulmonary arteries. CDC reported in 2002 Pulmonary artery hypertension (PAH) was the cause 
of 15,668 deaths and 260,000 hospitalizations in the U.S. PAH affects primarily older women; 
however, it is seen in both male and female of all ages and races
 5
.  Prior to 1995 the life 
expectancy of person with PAH was 3years since then average life expectancy has improved due 
to better treatment options.  The invention and use of pulmonary artery catheters (Swan-Ganz) 
have enabled clinicians to diagnose and treat PAH by measuring the pulmonary capillary 
pressure and thereby determining the pulmonary vascular resistance. This created the opportunity 
for early diagnosis/treatment and as a result prolonging life expectancy for those diagnosed.  
Normally the average pulmonary artery pressure is 25 mmHg at rest or 30 mmHg during 
physical activity. The world health organization divides PAH into five categories. The first 
category contains causes of PAH that have unknown origin, inherited, congenital or from HIV 
infection. Second group consist of PAH with heart disease. Third is PAH that coexist with lung 
diseases such as COPD. Fourth deals with PAH caused by blood clotting diseases such as 
pulmonary emboli polycythemia, or sickle cell anemia and fifth group includes causes such as 
Sarcoidosis, Langerhans cell Histioytosis, or tumor. In general, group one is considered primary 
PAH and those from 2
nd
 -5
th
 are secondary causes of PAH.  
Patients with PAH present with exertional dyspnea, fatigue on exertion, light 
headedness/weakness due to hypoxia and if leg edema develops it is often a sign of right sided 
heart failure. If PAH is not diagnosed and treated early, patients are more likely to develop Cor- 
Pulmonale. Normally, pressure in the pulmonary arteries is low allowing the RV to pump blood 
in to the lungs with little effort. However, in patients with PAH due to narrowing of the 
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pulmonary artery the RV has to compensate by using forceful contractions in order to overcome 
pulmonary artery resistance which leads to RV enlargement. Moreover, PAH increases RV 
susceptibility to ischemic injury and patients with right sided heart failure are at high risk for 
pulmonary embolism.  Definite diagnosis of PAH is made by pulmonary catheterization (swanz 
ganz cath) by measuring pressure in the RV and the pulmonary artery. However, exercise 
oximetry is a helpful diagnostic method as well. A fall in oxygen saturation without a history of 
lung parencymal disease is a strong indication for pulmonary vascular disease. In addition Chest 
x-ray can be used to detect cardiomegaly and Echocardiograpy is used to detect RV and LV 
function and valvular insufficiency.  
Arteries and lesions in the arterioles are the cause of the hypertension. Pulmonary 
endothelial dysfunction that leads to impaired production of vasodilators, such as nitric oxide, 
Prostacyclin, and over-expression of vasoconstrictors, such as Endothelin-1. These disease 
process lead to narrowing of the arteries. There are three classes of medications that are currently 
approved by the FDA. They are Prostacyclin (PGI2) analogues (Epoprostenol, Treprostinil, and 
Iloprost), Endothelin Receptor Antagonists (ERA) (Bosentan, Ambrisentan, and Sitaxsentan) and 
Phosphodiesterase inhibitors (PDEI) (Sildenafil, Tadalafil) 
4
. Other treatments include, 
Anticoagulants, diuretics, Digoxin, supplemental oxygen, OR calcium-channel blockers. If 
medication fails, Lung transplant is considered. The initial therapy of choice depends on cause of 
disease. Patients with Positive vasodilator response and WHO class I-III can be managed by 
CCB. Those with Negative vasodilator response or WHO class II or III are initiated with ERA or 
PDEI treatment.   
 
Objective: 
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The objective of this systematic review is to determine whether or not the 
Phosphodiesterase inhibitors drug Sildenafil Citrate is safe and effective treatment for Pulmonary 
Hypertension in adults 
 
METHODS: 
 The studies used for this review were selected based on the following criteria. The patient 
population was over the age of 18 and suffering from PAH. The intervention used was oral 
Sildenafil. The treatment groups were compared to placebo groups who received water pills. The 
outcomes measured were improvement of exercise capacity, improvement of 6minute walk, 
quality of life, hemodynamic measurements, and prevention of RVHF; all of these can qualify as 
patient oriented evidence that matter (POEM). All the three studies were randomized double 
blind, placebo-controlled 
 In research conducted by Shim et al, Fifty three patients with scheduled valvular heart 
surgery and systolic RV pressure >50mmHg and pulmonary pressure >30mmHgwere enrolled 
into the trial. Participants were randomly divided and given 50mg Sildenafil (n=26) or Placebo-
30ml sterile water (n-27) 10minutes before induction of anesthesia. Ten minutes before and five 
minutes after induction of anesthesia and 30 and 60 minutes after medication hemodynamic 
measurements were calculated. Badesch et al run a 12-week study on 278 PAH patients with 84 
subset of patients with connective tissue disease (CTD-PAH) with mean Pulmonary pressure 
>25mmHg and pulmonary artery wedge pressure <15mmHg at rest. Patients were randomly 
assigned into treatment and placebo groups. Those in treatment groups received Sildenafil at 
doses of 20mg TID, 40mg TID, or 80mg TID. Exercise capacity, Hemodynamic Measures and 
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WHO functional class and tolerability were assessed at week 4, 8 and 12weeks. Patients were 
excluded if they had a 6-minute walk distance (6MWD) of ≤ 100 m or ≥ 450 m. 
 Thirty four patients over the age of 18 who have chronic Heart failure despite standard 
HF therapies with secondary PAH (arterial pressure over 25mmHg) were enrolled in Lewis et al 
trial. Patients were randomized to 12-weeks treatment of Sildenafil (25-75mg orally TID) or 
placebo. Medication was initiated at 25mg then titrated up to 75mg TID over the course of every 
2weeks. Cardiopulmonary exercise testing was done before and after treatment in order to 
measure peak VO2. 22-gauge catheter was placed in the radial artery for continues measurement 
of mean arterial pressure and blood gas measurements were done at 1-minute intervals during 
cardiopulmonary exercise. Cardiac output at rest and during excersis was measured using Fick 
Oxygen technique.  
 Key words used in searches were Pulmonary Hypertension, pulmonary arterial 
hypertension, pulmonary hypertension, Sildenafil, Viagra. All articles were published in an 
English langue in peer-reviewed journals. This author personally did the article search in OVID 
Medline and Cochran database. Inclusion criteria were: patients over the age of 18, randomized, 
POEM, RCT’s, articles published between 1996 and the present and not used in any prior meta-
analysis or systematic review publications. Exclusion criteria were: Patients under 18y.o, 
Disease-oriented evidence (DOE) trials, studies published before 1996, and articles used in prior 
meta-analysis or systematic review publications 
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Study Type # 
Pts 
Age Inclusion 
Criteria 
Exclusion Criteria W/D Intervention 
Shim, 
2006 
(1) 
Double blind 
RCT 
 
53 Mean 
age 53-
57 
Pts with 
concomitant 
pulmonary 
hypertension 
undergoing 
valvular surgery 
with pulmonary 
arterial pressure 
greater than 
30mmHg  
 
Pts w/ preexisting 
lung parenchymal 
disease, coronary 
artery occlusive 
disease, hepatic or 
renal disease, TR 
of at least 2, or 
NYHA functional 
class of at least 3, 
and pts taking 
nitrates were 
excluded. 
7 50mg Oral 
Sildenafil given 
10min before 
anesthesia 
 
Badesch, 
2007 
(2) 
Randomized, 
double blind, 
placebo-
controlled 
study 
278 Mean 
50-56 
Pts w/ 
Connective 
tissue disease, 
>18yo 
Pts w/ 6-minute 
walk distance 
(6MWD) of ≤ 100 
m or ≥ 450 m 
5 Oral Sildenafil  
in three dose 
groups (20, 40, 
80 Mg tid) 
 
Lewis, 
2007 
(3) 
Randomized, 
double blind, 
placebo-
controlled 
study 
34 Mean 
age 54-
62 
>18 y.o. w/ , 
LVSD and 
NYHA class II 
to IV CHF 
despite standard 
HF therapies. 
Pts w/ 
secondary PH 
pressure >25 
mm Hg 
Pts w/ a noncardiac 
limitation to 
exercise, 
provocable 
ischemia, 
hemodynamic 
instability, or 
ongoing nitrate 
therapy 
3 Oral Silddenafil  
25-75mg 3xday 
 
 
 
OUTCOMES MEASURED 
 Pulmonary hypertension causes right ventricular failure. If pulmonary hypertension rises, 
RV is susceptible to ischemic injury. So the done by Shim et al tried measured systolic 
pulmonary atrial pressure (SPAP), MPAP, Central venous pressure, RV ejection fraction, RV 
end-systolic/diastolic volume index, and pulmonary vascular resistance index. In Badesch et al 
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study the outcomes were measured using exercise capacity from base line and hemodynamic 
measurements (mPAP, mean right atrial pressure (mRAP), cardiac output, and pulmonary 
vascular resistance (PVR)). 
Lewis et al measured Oxygen uptake (VO2), carbon dioxide output (VCO2), and 
respiratory exchange ratio, cardiac output, systemic vascular resistance and PVR at rest and 
during exercise. Right atrial, pulmonary aterial and pulmonary wedge pressure were measured 
while patient was upright on bicycle or sitting during cardiopulmonary exercise. Also, 6minute 
walk distance was measured at baseline, 6weeks and at 12week 6-min walk distance and mean 
pulmonary arterial pressure was calculated. After completion of these measurements, patients 
were given a questionnaire (21 questions to assess their quality of life) with scores ranging from 
0-5 for each question and. Measured VO2 during exercise and at rest using Fick oxygen 
Technique. 
 
RESULTS  
 All three of the articles presented double blinded, randomized control trials. Shim et al 
addressed the effects of Sildenafil citrate on patients with PAH who were undergoing vascular 
heart surgery. The study had 53 participants with mean age of 57 for control groups and mean 
age of 53 for control groups. Ratio of male to females was equal in both control and treatment 
groups. Badesch et al conducted research on 278 patients with PAH and 84 subgroup of patients 
with CTD-PAH. Of the 278 patients, 94 completed the study. Majority of the patients were 
women, patients with scleroderma and those in factional category III. Most common non-dose 
related sildenafil side effects noted among patients were Headache and epistaxis. During the 
trial, 5 patients dropped out of the treatment group. Three patients died (cause of death: MI, PE, 
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Urosepsis) and two patients discontinued due to lower leg edema and cirrhosis of the liver. None 
of these deaths were attributed to treatment with sildenafil.  
 Lewis et al studied thirty four patients with LVSD in NYHA class II-IV with PAH were 
enrolled in trial for 12 weeks. These participants had previously shown 2-4% increase in peak 
VO2 after one time treatment of Sildenafil. In total, four patients withdrew from trial (two from 
each group) and no deaths occurred. One patient from treatment group withdrew after elective 
implantation of cardiac resynchronization device and second one due to ventricular tachycardia 
with syncope. In placebo group, one patient withdrew due to pruritis and another due to 
worsening HF. As with Badesch et al trial, the most common side effect noted in this trial was 
headache. About 41% of patients treated with sildenafil complained of Headache. In addition, at 
the end of the trial fewer patients in the treatment groups were hospitalized compared to those in 
placebo group (P=0.046).  
The data in shim et al study was presented in Continuous data form using x
2
 test. At T0 
there was no significant hemodynamic variables difference from baseline between control and 
treatment groups. At T30, SPAP, MPAP, and PVRI were significantly lower in sildenafil group 
compared to control groups; moreover, SPAP and MPAP at T30 were significantly lower in 
sildenafil group compared to baseline values. At T0 hemodynamic values are similar between all 
groups with no statistical significance (SPAP: P=0 .07; MPAP: P= 0 .087; PVRI:  P=0 .09). 
There was little total significant difference between control and treatment groups with the 
exception of PVRI. P value for PVRI was statistically significant difference between treatment 
group and placebo group (P=0.04) 
 Patients in Badesch et al treated with Sildenafil showed had an increase in 6minute 
walking distance compared to control groups after 12weeks of treatment with a mean increase of 
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55m at the end of week 12. After 12 weeks of treatment the treatment group with 20mg had a 
mean increase of 42m and those treated with 40mg had an increase of 36m and with 80mg of 
Sildenafil there was an increase of 15m. Patients in treatment group showed an improvement in 
WHO functional class following the 12-week treatment. Patients treated with 80mg of Sildenafil 
had 42% changes, greater than the other two treatment groups. This data were converted from 
“continuous data” form to “Dichotomous” data. Experimental event rate (EER) was 42%; this is 
the percentage of patients who showed an improvement after treatment with 80mg of Sildenafil. 
The Control event rate (CER) was 5%, meaning the % of patients who showed an improvement 
in controlled group. From this numbers RRR and ARR were calculated.  An absulute risk 
reduction (ARR) of 0.37 and the Relative risk reduction (RRR) was 7.4. the number needed to 
treat  (NNT) was 2.7. Hemodynamic measurements only showed improvement in only those 
treated with 20mg TID achieved a statstical significant change with P<0.01 of mPAP and p<0.05 
of PVR 
 Measured exercise capacity of patients by measuring their peak VO2. Patients treated 
with Sildenafil had VO2 increase from 12.2+0.7 to 13.9+1.0 mL/kg/ min with P=0.02; while vo2 
did not change in placebo group. In addition patients in treatment groups had greater change in 
their peak VO2 from base line compared to control group. Anothere variable measured was 
cardiac output. Patiets treated with medication had an increase in CO. the increase in Peak VO2 
in treatment group lead to an improvement in PVR (p=0.002) and RV ejection fraction (p=0.01). 
patients had improved EVEF at rest and peak exercise (p=0.03; p=0.04 respectively); while no 
change was observed in placebo group  at the end of 12 weeks resting PVR (20+6%; P=0.02) 
and in PVR/SVR (-16+6%; P=0.01) indicating sildenefil has a selective vasodilator effect. 
Patients in intreatment groups had also an increase in their 6MWD  by 62m (p=0.004). The study 
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also measured patients quality of life by using a questioniar. NYHA cass improved in 53% of 
sildenfil treatmentpatients while only 7% improved in placebo group (p=0.045). Patients 
receiving medication saw a reduction in N-terminal BNP levels at week 12 compared to placebo 
(p=0.11).  
 
DISCUSSION 
 Sildenafil is the only FDA approved Phosphodiestrase inhibitor to PAH. 
Phosphodiesterase Inhibitors works by slowing the metabolism of intracellular cGMP. cGMP is 
activated by NO and Prostacyclins leading to relaxation of vascular smooth muscle. Sildenafil is 
marketed under trade name Revatio for PAH and Viagra for erectile dysfunction. It peaks an 
hour after first ingestion and has 3.7 hours of half life. It is associated with Headache and Visual 
blurriness. Two trials by Levi et al and Badesch et al showed a statistically significant 
improvement in outcomes they measured. In these studies, Sildenafil treatment improved 
exercise capacity, Hemodynamic measurements and improved patients’ functional class in 
Patients with CTD-PAH compared to placebo group. Also Systolic heart failure patients with 
PAH that were enrolled in sildenafil treatment group had an improved exercise capacity, 6-
minute walking distance, improved quality of life and decreased hospital admission. However, 
trial conducted on patients that were undergoing valvular heart surgery did not show statistically 
significant difference between treatment and control groups. The most important clinical 
significant of this trial was to determine the effect of sildenafil on homodynamic measurements 
because this measurements directly reflect PAH. There by decreased pulmonary pressure can 
preserve coronary perfusion leading to decreased complications due to RV ischemia and 
subsequent RV dysfunction. Limitations of these three trials were their small sample size (it 
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ranged from 34-53), short duration of trial period with the longest being 12wks and none of the 
trials included comprehensive long-term treatment follow-up. Small sample sizes may be good 
for limiting sample variables; however, larger data sizes give a more concrete and strong 
correlations.  
CONCLUSION 
 Although, treatment with sildenafil did not  show efficacy in patients undergoing vascular 
surgery, the other two studies done on CTD-PAH and Systolic heart failure patients showed 
Sildenafil is effective in improving 6-MWD, quality of life and hemodynamic measurements. 
Furthermore, compared to medications used for PAH, Sildenafil has fewer numbers of side 
effects. The dilatory effect of Sildenafil leads to decreased vascular pressure which in turn 
increases cardiac output and EF. The increase in cardiac output and EF has direct effect on 
improving patients’ quality of life by decreasing dyspnea, fatigue and other symptoms. All the 
studies measured atrial pressure to determine the effects of sildenafil; however, atrial pressure 
depends on different variables. Larger study with larger number of participants that run longer 
period of time is needed to show long term benefits and complications. Future researches in this 
arena should focus on how sildenafil compares to other drugs that treat PAH. How it differs and 
how its potential benefits compare to other drugs. These studies focused primarily on 
hemodynamic measurements. It would be interesting to included patient feedback through 
surveys on their quality of life improvement.  
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